Amarin | AMRN - Operating Expenses


Amarin reported $51.37M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
AbbVie USD 10.81B 13.45B Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amarin USD 51.37M 14.6M Sep/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
GlaxoSmithKline GBP 7.18B 1.42B Dec/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Heron Therapeutics USD 38.47M 4M Sep/2024
Ionis Pharmaceuticals USD 316.9M 4.69M Sep/2025
Nektar Therapeutics USD 85.09M 109.3M Sep/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novartis USD 9.86B 115M Sep/2025